Farmacocinética poblacional de la digoxina en pacientes de edad avanzada: Una revisión sistemática
Resumen
Objetivo: Resumir la literatura disponible sobre los estudios de farmacocinética poblacional de digoxina en pacientes de edad avanzada e identificar los cambios fisiopatológicos en esta subpoblación, que conllevan implicaciones clínicas en la farmacocinética de la digoxina.
Método: Se realizó una revisión sistemática de los estudios de farmacocinética poblacional en pacientes ancianos que recibían digoxina. Se utilizaron PubMed, ISI Web of Science, SCOPUS y Science Direct para identificar los artículos con los descriptores (“Digoxin”[Mesh]) AND (“Pharmacokinetics”[Mesh]) AND (“Aged”[Mesh] OR “Elderly”[Mesh]), seguido de una búsqueda manual.
Resultados: Se encontraron y revisaron nueve estudios, cinco de los cuales de desarrollaron en pacientes asiáticos. Se utilizó NONMEM para el análisis farmacocinético de los niveles plasmáticos de la digoxina, mayoritariamente descrita como un modelo monocompartimental.
Conclusiones: Los pacientes ancianos presentan cambios fisiopatológicos con gran influencia en la farmacocinética de muchos fármacos. Las covariables con un mayor impacto en la farmacocinética de la digoxina deben tenerse en cuenta al ajustar la dosis de este medicamento en pacientes de edad avanzada con el fin de lograr beneficios óptimos para la salud y prevenir posibles efectos adversos en esta subpoblación.
Palabras clave
Referencias
Hanratty CG, McGlinchey P, Johnston GD, Passmore AP. Differential pharmacokinetics of digoxin in elderly patients. Drugs Aging. 2000;17(5):353-62. DOI: 10.2165/00002512-200017050-00003
Tripathi KD. Essentials of Medical Pharmacology. 7.ª ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2013.
Currie GM, Wheat JM, Kiat H. Pharmacokinetic considerations for digoxin in older people. Open Cardiovasc Med J. 2011;5:130-5. DOI: 10.2174/1874192401105010130
Patockaa J, Nepovimovac E, Wu W. Digoxin. Pharmacology and toxicology—A review. Environ Toxicol Pharmacol. 2020;79:103400. DOI: 10.1016/j.etap.2020.103400
Dewan P, Jhund PS, Shen L. Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. Eur J Heart Fail. 2019;21(5):577-87. DOI: 10.1002/ejhf.1347
De Lannoy IA, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun. 1992;189:551-7. DOI: 10.1016/0006-291x(92)91593-f
Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al. MDR-1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001;18:1400-4. DOI: 10.1023/a:1012244520615
Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004;109:2959-64. DOI: 10.1161/01.CIR.0000132482.95686.87
United Nations, Department of Economic and Social Affairs, Population Division. World Population Ageing 2019: Highlights (ST/ESA/SER.A/430). Nueva York; 2019. Available at: chrome- extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.un.org/en/ development/desa/population/publications/pdf/ageing/WorldPopulationA geing2019-Highlights.pdf
Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41:67-76. DOI: 10.1080/03602530902722679
Ewing AB. Altered drug response in the elderly. En: Armour D, Cairns C, eds. Medicines in the elderly. London: Pharmaceutical Press; 2002.
Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38:843-53. DOI: 10.1016/s0531-5565(03)00133-5
Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, et al. Development of a whole-body physiologically based pharmacokinetic approach to assess the pharmacokinetics of drugs in elderly individuals. Clin Pharmacokinet. 2016;55:1573-89. DOI: 10.1007/s40262-016- 0422-3
McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004;56:163-84. DOI: 10.1124/pr.56.2.4
Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. Br J Clin Pharmacol. 2003;57:6-14. DOI: 10.1046/j.1365-125.2003.02007.x
Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet. 2008;47:297-321. DOI: 10.2165/00003088-200847050-00002
Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115-21. DOI: 10.1067/mcp.2002.121829
Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23(1):19-28. DOI: 10.1053/j.ackd.2015.08.004
Glassock RJ, Rule AD. The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli. Kidney Int. 2012;82(3):270-7. DOI: 10.1038/ki.2012.65
Wiggins JE. Aging in the glomerulus. J Gerontol A Biol Sci Med Sci. 2012;67(12):1358-64. DOI: 10.1093/gerona/gls157
Delafuente JC. Pharmacokinetic and pharmacodynamic alterations in the geriatric patient. Consult Pharm. 2008;23:324-34. DOI: 10.4140/tcp.n.2008.324
El Desoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther. 2007;14:488-98. DOI: 10.1097/01.mjt.0000183719.84390.4d
Kostrzewski A. Cardiovascular medicines in the elderly. En: Armour D, Cairns C, eds. Medicines in the elderly. London: Pharmaceutical Press; 2002.
Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;19:871-8. DOI: 10.1001/jama.289.7.871
Ehle M, Patel C, Giugliano RP. Digoxin: clinical highlights: a review of digoxin and its use in contemporary medicine. Crit Pathol Cardiol. 2011;10(2):93-8. DOI: 10.1097/HPC.0b013e318221e7dd
Wofford JL, Ettinger WH. Risk factors and manifestations of digoxin toxicity in the elderly. Am J Emerg Med. 1991;9(2 Suppl 1):11-5. DOI: 10.1016/0735-6757(91)90161-c
Cusack B, Kelly J, O’Malley K, Noel J, Lavan J, Horgan J. Digoxin in the elderly: pharmacokinetic consequences of old age. Clin Pharm Ther. 1979;25:772-6. DOI: 10.1002/cpt1979256772
Rheu YM, Shin WG, Choi JS. Population pharmacokinetics of digoxin in Korean clearance after the multiple intravenous administrations. J Korean Soc Clin Pharmacol Ther. 1997;5(1):42-52.
Suematsu F, Minemoto M, Yukawa E, Higuchi S. Population analysis for the optimization of digoxin treatment in Japanese pediatric patients. J Clin Pharm Ther. 1999;24:203-8. DOI: 10.1046/j.1365-2710.1999.00221.x
Gong Y, Chen Y, Li Q, Li Z. Population pharmacokinetic analysis of digoxin in Chinese neonates and infants. J Pharmacol Sci. 2014;125:142-9. DOI: 10.1254/jphs.13233fp
Suematsu F, Yukawa E, Yukawa M, Minemoto M, Ohdo S, Higuchi S, et al. Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-trough screen analysis. Eur J Clin Pharmacol. 2001;57:19-24. DOI: 10.1007/s002280100274
El Desoky ES, Nagaraja NV, Derendorf H. Population pharmacokinetics of digoxin in Egyptian pediatric patients: Impact of one data point utilization. Am J Ther. 2002;9(6):492-8. DOI: 10.1097/00045391-200211000-00006
Martín-Suárez A, Falcao AC, Outeda M, Hernández FJ, González MC, Quero M, et al. Population pharmacokinetics of digoxin in pediatric patients. Ther Drug Monit. 2002;24:742-5. DOI: 10.1097/00007691- 200212000-00010
Yukawa E, Akiyama K, Suematsu F, Yukawa M, Minemoto M. Population pharmacokinetic investigation of digoxin in Japanese neonates. J Clin Pharm Ther. 2007;32(4):381-6. DOI: 10.1111/j.1365- 2710.2007.00833.x
Preechagoon Y, Somsaard P, Petcharattana S. Population pharmacokinetics of digoxin in Thai pediatric patients. J Med Assoc Thai. 2009;92(10):1324-35.
Yukawa M, Yukawa E, Suematsu F, Takiguchi T, Ikeda H, Aki H, et al. Population pharmacokinetic investigation of digoxin in Japanese infants and young children. J Clin Pharmacol. 2011;51(6):857-63. DOI: 10.1177/0091270010374475
Jelliffe RW, Milman M, Schumitzky A, Bayard D, Van Guilder M. A two-compartment population pharmacokinetic-pharmacodynamic model of digoxin in adults, with implications for dosage. Ther Drug Monit. 2014;36(3):387-93. DOI: 10.1097/FTD.0000000000000023
Abdel Jalil MH, Abdullah N, Alsous MM, Saleh M, Abu-Hammour K. A systematic review of population pharmacokinetic analyses of digoxin in the pediatric population. Br J Clin Pharmacol. 2020;86(7):1267-80. DOI: 10.1111/bcp.14272
Nagaraja NV, Park YJ, Jeon S, Sands CD, Derendorf H. Population pharmacokinetics of digoxin in Korean patients. Int J Clin Pharmacol Ther. 2000;38(6):291-7. DOI: 10.5414/cpp38291
Suematsu F, Yukawa E, Yukawa M, Minemoto M, Ohdo S, Higuchi S, et al. Pharmacoepidemiologic detection of calcium channel blocker- induced change on digoxin clearance using multiple trough screen analysis. Biopharm Drug Dispos. 2002;23(5):173-81. DOI: 10.1002/bdd.306
Konishi H, Shimizu S, Chiba M, Minouchi T, Koida M, Yamaji A. Predictive performance of serum digoxin concentration in patients with congestive heart failure by a hyperbolic model based on creatinine clearance. J Clin Pharm Ther. 2002;27(4):257-65. DOI: 10.1046/j.1365- 2710.2002.00418.x
Hornestam B, Jerling M, Karlsson MO, Held P, DAAf Trial Group. Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial. Eur J Clin Pharmacol. 2003;58(11):747-55. DOI: 10.1007/s00228-002-0553-3
Williams PJ, Lane J, Murray W, Mergener MA, Kamigaki M. Pharmacokinetics of the digoxin-quinidine interaction via mixed-effect modelling. Clin Pharmacokinet. 1992;22(1):66-74. DOI: 10.2165/00003088-199222010-00006
Choi SA, Yun HY, Lee ES, Shin WG. A population pharmacokinetic analysis of the influence of nutritional status of digoxin in hospitalized Korean patients. Clin Ther. 2014;36(3):389-400. DOI: 10.1016/j.clinthera.2014.01.019
Chen R, Zou SL, Wang ML, Jiang Y, Xue H, Qian CY, et al. Population pharmacokinetics of digoxin in elderly patients. Eur J Drug Metab Pharmacokinet. 2013;38:115‑21. DOI: 10.1007/s13318-012-0107-8
Komatsu T, Morita M, Miyaji F, Inomata T, Ako J, Atsuda K. Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients. J Pharm Health Care Sci. 2015;25;1:25. DOI: 10.1186/s40780-015-0023-6
Bauer LA, Horn JR, Pettit H. Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations. Ther Drug Monit. 1996;18(1):46-52. DOI: 10.1097/00007691-199602000-00008
Yukawa M, Yukawa E, Suematsu F, Takiguchi T, Ikeda H, Aki H, et al. Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy. A population pharmacokinetic analysis using nonlinear mixedeffects modelling. Drugs Aging. 2011;28:831-41. DOI: 10.2165/11594230-000000000-00000
Zhou XD, Gao Y, Guan Z, Li ZD, Li J. Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice. Acta Pharmacol Sin. 2010;31:753-8. DOI: 10.1038/aps.2010.51
Yukawa E, Mine H, Higuchi S, Aoyama T. Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. J Pharm Pharmacol. 1992;44:761-5. DOI: 10.1111/j.2042-7158.1992.tb05515.x
Abdel-Jalil M, Abdullah N, Alsous M, Abu-Hammour K. Population Pharmacokinetic Studies of Digoxin in Adult Patients: A Systematic Review. Eur J Drug Metab Pharmacokinet. 2021;46(3):325-42. DOI: 10.1007/s13318-021-00672-6
Du P, Wang A, Ma Y, Jia A, Li Y, Li X. Impact of SLCO4C1 genotypes, creatinine, and spironolactone on digoxin population pharmacokinetic variables in patients with cardiac insufficiency. Clin Ther. 2020;42(9):1799-810.e3. DOI: 10.1016/j.clinthera.2020.07.011
Yukawa E, Honda T, Ohdo S, Higuchi S, Aoyama T. Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update. J Clin Pharmacol. 1997;37(2):92-100. DOI: 10.1002/j.1552-4604.1997.tb04766.x
Yukawa E, Suematu F, Yukawa M, Minemoto M, Ohdo S, Higuchi S, et al. Population pharmacokinetics of digoxin in Japanese patients. A 2- compartment pharmacokinetic model. Clin Pharmacokinet. 2001;40:773-81. DOI: 10.2165/00003088-200140100-00005
Dartois C, Brendel K, Comets E, Laffont CM, Laveille C, Tranchand B, et al. Overview of model-building strategies in population PK/PD analyses: 2002–2004 literature survey. Br J Clin Pharmacol. 2007;64(5):603-12. DOI: 10.1111/j.1365-2125.2007.02975.x
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. DOI: 10.1186/2046-4053-4-1
Koup JR, Jusko WJ, Elwood CM, Kohli RK. Digoxin pharmacokinetics: role of renal failure in dosage regimen design. Clin Pharmacol Ther. 1975;18(1):9-21. DOI: 10.1002/cpt19751819
Rabkin SW, Grupp G. A two compartment open model for digoxin pharmacokinetics in patients receiving a wide range of digoxin doses. Acta Cardiol. 1975;30(5):343-51.
Kramer WG, Lewis RP, Cobb TC, Forester WF Jr, Visconti JA, Wanke LA, et al. Pharmacokinetics of digoxin: comparison of a two- and a three-compartment model in man. J Pharmacokinet Biopharm. 1974;2(4):299-312. DOI: 10.1007/BF01061404
Writing Committee Members, Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. Heart Rhythm. 2019;16(9):e227-79. DOI: 10.1016/j.hrthm.2018.10.036
Chiang JY, Chen PC, Yang YH, Chang CH, Chu FY, Chen JJ, et al. Digoxin-amiodarone combination is associated with excess all-cause mortality in patients with atrial fibrillation. Sci Rep. 2020;10(1):4101. DOI: 10.1038/s41598-020-61065-4
Cobo A, Martín-Suárez A, Calvo MV, Domínguez-Gil A, Fernández de Gatta MM. Clinical repercussions of analytical interferences due to aldosterone antagonists in digoxin immunoassays: an assessment. Ther Drug Monit. 2010;32(2):169-76. DOI: 10.1097/FTD.0b013e3181cdc93e
DeFrance A, Armbruster D, Petty D, Cooper KC, Dasgupta A. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone. Ther Drug Monit. 2011;33(1):128-31. DOI: 10.1097/FTD.0b013e3181fd4c30
DOI: http://dx.doi.org/10.7399%2Ffh.13288
Enlaces refback
- No hay ningún enlace refback.
Incluida en:
Farmacia Hospitalaria
Sociedad Española de Farmacia Hospitalaria. C/ Serrano n. 40 2º Dcha. - 28001 Madrid
eISSN: 2171-8695
ISSN-L: 1130-6343
Dep. Legal: M-39835-2012
Correo electrónico de contacto: [email protected]
Los artículos publicados en esta revista se distribuyen con la licencia: Creative Commons Attribution 4.0.
La revista Farmacia Hospitalaria no cobra tasas por el envío de trabajos, ni tampoco cuotas por la publicación de sus artículos.